AstraZeneca, Lupin Soothe Nexium Patent Fight

Law360, New York (January 26, 2012, 8:10 PM EST) -- Pharmaceutical giants AstraZeneca AB, Merck Sharp & Dohme Corp. and KBI Inc. reached a settlement Thursday with Indian drugmaker Lupin Ltd. in a patent dispute over stomach acid reflux drug Nexium.

U.S. District Judge Joel A. Pisano signed off on the settlement agreement — whose terms were not publicly disclosed — dismissing all claims in the dispute without prejudice and without costs or attorneys’ fees to any of the parties in the dispute.

Sweden-based AstraZeneca and New Jersey-based KBI had sued Lupin in October 2009, claiming...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.